FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.

Authors :: Chang, Elaine
Gittleman, Haley
Song, Chi
Bloomquist, Erik
Weinstock, Chana
Agrawal, Sundeep
Sridhara, Rajeshwari
Gormley, Nicole
Amiri-Kordestani, Laleh
Tang, Shenghui
Suzman, Daniel L.
Pazdur, Richard
Kluetz, Paul Gustav
McDermott, David F.
Regan, Meredith M.
Rini, Brian I.
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p418-418, 140p
Publication Year :: 2024

Full Text Access

Tools